Astex Announces Clinical Trial Authorization for Novel Cancer Drug AT7519 and Plans for Two Further New Drug Filings in the Next Nine Months

Cambridge, UNITED KINGDOM


CAMBRIDGE, U.K., May 23, 2005 (PRIMEZONE) -- Astex:


 -- Astex announces first CTA for novel cancer drug

 -- AT7519 went from first synthesis to CTA approval in just 14 months 
    -- less than half the industry average

 -- Signifies transition from platform to product company

Full press release attached below: http://hugin.info/132636/R/995337/150883.pdf


        

Contact Data